ПЕРИФЕРИЧНА Т-КЛІТИННА ЛІМФОМА НЕУТОЧНЕНА: РЕЗУЛЬТАТИ ДОСЛІДЖЕННЯ В ОДНОМУ ЦЕНТРІ

• Дата: 2023
• Автори: Kriachok, I., Tytorenko, I., Shudrak, N., Aleksik, O., Stepanishyna, Ya., Kadnikova, T., Pastushenko, Ya., Shokun , N., Rudiyk, T., Bushuieva, M.
• Формат: Стаття
• Мова: English
• Опубліковано: PH Akademperiodyka 2023
• Теми: T-клітинна лімфома; T-клітинна лімфома неуточнена; захворюваність; прогностичний фактор; відповідь на лікування; виживаність
• Онлайн доступ: https://exp-oncology.com.ua/index.php/Exp/article/view/2023-4-474
• Назва журналу: Experimental Oncology

Background. The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response. Patients and Methods. An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP — cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18). Results. The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (> 65%) was a negative prognostic factor. Conclusions. The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.